FANGZHOU JIANKE (06086): The news of the H2H tournament is not insider information, I do not know the reason for the stock price rise.

FANGZHOU JIANKE (06086) announced that the Board of Directors has noted that the company's shares have recently seen an increase in price on the Hong Kong Stock Exchange as of September 12, 2025. The Board also noted that the company issued a press release regarding its participation in the 10th H2H Medical Service Ecological Conference held on September 10, 2025. The press release included several pieces of company news, including: (i) the company's launch of the proprietary "Apricot Stone" large model as the cornerstone of its five flagship applications (AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search), empowering advanced clinical diagnostic support and personalized chronic disease management; (ii) strategic partnership with INNOVENT BIO pharmaceuticals, integrating the Ark H2H digital health ecosystem with the Sinda weight management therapy pipeline, initially using the company's Apricot Stone large model to provide personalized digital maintenance and compliance support for Sinda's Masidu peptide, improving patient efficacy in the rapidly growing weight management market in China; and (iii) strategic cooperation with Zhejiang Daiichi Pharmaceutical Co., Ltd., combining the company's AI technology advantages with Daiichi's innovative drug combinations, jointly developing a comprehensive digital solution covering drug support services, targeted patient outreach projects, and health education programs. Following a reasonable inquiry on the relevant circumstances of the company, the Board confirms that the information contained in the press release does not constitute insider information under Rule 13.09(2) of the Listing Rules or the insider trading provisions under Part XIVA of the Securities and Futures Ordinance of Hong Kong. The Board is also not aware of any reasons for the increase in share price or any information that would require disclosure to avoid a false market in the company's shares or any insider information that needs to be disclosed.